SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported)
February 19, 2018
Wize Pharma, Inc.
(Exact Name of Registrant as Specified in
|(State or Other Jurisdiction
||(Commission File Number)
||(IRS Employer |
| 5b Hanagar Street, Hod Hasharon, Israel
|(Address of Principal Executive Offices)
Registrant’s telephone number, including
area code: +(972) 72-260-0536
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
||Written communications pursuant to Rule 425 under the Securities Act|
||Soliciting material pursuant to Rule 14a-12 under the Exchange Act|
||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act|
||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 5.07. Submission of Matters
to a Vote of Security Holders.
On February 19, 2018,
a special meeting of stockholders (the “Meeting”) of Wize Pharma, Inc. (the “Company”) was held at 10:00
a.m. local time at the law offices of Goldfarb Seligman & Co., 98 Yigal Alon St., Tel Aviv, Israel. At the Meeting, a total
of 63,736,572 shares, or 61.04%, of the Company’s common stock issued and outstanding as of the record date for the Meeting
were represented in person or by proxy. Set forth below is a brief description of the matter voted upon at the Meeting and the
voting results with respect to the matter.
1) To grant the Board
of Directors the authority, in its sole direction, to approve an amendment to the Company’s Certificate of Incorporation
to effect a reverse stock split of the Company’s issued and outstanding common stock by a ratio of not less than one-for-ten
and not more than one-for-two hundred at any time prior to February 19, 2019, with the exact ratio to be set at a whole number
within this range as determined by the Board of Directors.
|Votes For|| ||
||Votes Against|| ||
| ||63,736,072|| ||
|| ||500|| ||
|| ||0|| |
At the Meeting, the
stockholders approved the amendment to the Company’s Certificate of Incorporation to effect a reverse stock split of the
Company’s issued and outstanding common stock by a ratio of not less than one-for-ten and not more than one-for-two hundred,
with the exact ratio to be set at a whole number within this range as determined by the Board of Directors.
Pursuant to the requirements
of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
||Wize Pharma, Inc.|
|Date: February 20, 2018
||/s/ Or Eisenberg |
||Acting Chief Executive Officer,|
Chief Financial Officer, Treasurer and Secretary